Pneumococcal Pneumonia and the Limits of Antimicrobial Therapy
The mortality of pneumococcal pneumonia decreased from 30% to about 10% in past century with the development of effective therapy, first in the form of serotherapy and then antimicrobial drugs. However, most of the progress in reducing the mortality of pneumococcal pneumonia was made in the mid-20th century and recent decades may have witnessed some backsliding with the emergence of antimicrobial resistance and higher mortality in immunosuppressed individuals. Hence, we may be reaching the asymptote of antimicrobial efficacy and future progress in reducing mortality could require helping the host in addition to killing the microbe.
Authors
- Arturo Casadevall (ORCID: https://orcid.org/0000-0002-9402-9167)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1093/infdis/jiag556
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00